Did you know that the 100-year-old BCG is the only vaccine available to protect against TB, and the world urgently needs a better TB vaccine?

There are several vaccine candidates in the pipeline, and our VPM1002 is one of the most advanced ones. The Scientist reported about the latest updates in the TB vaccine development. Click here to read the full article.

We are pleased to announce that all clinical trial centers, located in Kenya, Tanzania, Uganda, South Africa and Gabon, have started their recruitment and are actively enrolling participants into the pivotal phase III trial (priMe) of the novel tuberculosis vaccine VPM1002.

Vakzine Projekt Management supports Memo Therapeutics AG in the clinical development of MTX-COVAB, human-derived antibody against SARS-CoV-2 which has shown excellent neutralizing efficacy against both the original virus as well as the UK variant.

The local newspaper in Gauteng, South Africa, reported about the priMe study.

We are pleased to announce that a major milestone in the pivotal phase III trial (trial name: priMe) of the novel tuberculosis vaccine VPM1002 has been achieved with the completed initiation of all clinical trial centers. Read more!

TB vaccine candidate being investigated to prevent TB infection in infants in Phase III priMe study. Read more!

Vakzine Projekt Management GmbH (VPM) announces that the first clinical center in South Africa has been initiated in a large phase III trial (priMe) to assess the efficacy and safety of the novel TB vaccine – VPM1002 – in comparison with BCG in healthy newborn infants. The clinical centers in Tanzania, Uganda and Gabon will follow in the next weeks.

Vakzine Projekt Management GmbH (VPM) announces that the first participant has been enrolled